Cynata’s Pivotal aGvHD and Osteoarthritis Trials Miss Primary Endpoints

Cynata Therapeutics has reported negative topline results from two pivotal clinical studies evaluating its mesenchymal stem cell-based therapies. The Phase 2 trial of CYP-001 in acute graft-versus-host disease (aGvHD) and the Phase 3 SCUlpTOR study of CYP-004 in knee osteoarthritis (OA) both failed to achieve their primary endpoints, marking a significant setback for the Australian regenerative medicine company.

Neither study demonstrated statistically significant differences between active treatment and control groups across primary or key secondary efficacy measures. However, both programs continued to show favorable safety and tolerability profiles, with adverse event rates comparable to control arms.

Stem Cell Platform Targets High-Unmet-Need Diseases

Cynata develops off-the-shelf mesenchymal stem cell (MSC) therapies generated from induced pluripotent stem cells (iPSCs). The platform aims to overcome manufacturing limitations associated with donor-derived MSC products while providing a scalable source of therapeutic cells.

Acute graft-versus-host disease remains a serious and potentially fatal complication following allogeneic stem cell transplantation, with limited treatment options for patients who fail steroid therapy. Knee osteoarthritis affects millions worldwide and lacks disease-modifying therapies capable of slowing cartilage degeneration while providing sustained symptom relief.

Phase 2 aGvHD Trial Fails to Replicate Earlier Signals

The aGvHD study (NCT05643638) evaluated CYP-001 in patients with acute graft-versus-host disease. The trial did not show meaningful differences between treatment and control groups in either the primary endpoint or key secondary outcomes.

Day 28 overall response rates reached 57.7% in the CYP-001 group compared with 54.8% in controls. Complete response rates at Day 28 were similarly comparable at 38.5% and 35.5%, respectively. Additional measures, including Day 100 response rates, durable responses, and overall survival, also failed to demonstrate a treatment advantage.

The outcome contrasted sharply with earlier Phase 1 findings, which had generated encouraging efficacy signals and supported advancement into controlled studies.

Phase 3 Osteoarthritis Study Misses Co-Primary Endpoints

The SCUlpTOR Phase 3 trial (ACTRN12620000870954) evaluated CYP-004 in knee osteoarthritis over 24 months. The study failed to meet both co-primary endpoints.

Among treated patients, 51.7% achieved the patient-acceptable symptom state threshold for knee pain compared with 48.1% in the control group. The study also showed no significant difference in cartilage preservation, with central medial femorotibial cartilage thickness loss measuring 0.27 mm in the active group versus 0.21 mm in controls.

Although patients receiving CYP-004 experienced substantial and durable reductions in pain from baseline through 24 months, a similarly strong response in the control group prevented demonstration of a statistically significant treatment effect.

Management Highlights Unexpected Findings

Company leadership described the results as surprising, particularly in aGvHD, where earlier clinical data had supported confidence in the program’s potential. Management noted that the osteoarthritis study produced meaningful pain improvements in treated patients, but an unusually robust placebo response complicated efficacy interpretation.

Neither study identified new safety concerns, reinforcing the favorable tolerability profile previously observed across the company’s MSC programs.

Clinical Path Forward

Cynata is continuing analyses of additional outcome measures from the SCUlpTOR trial and plans to report further findings as they become available. The company is also assessing the implications of both readouts for its broader development strategy.

While the dual failures significantly impact near-term clinical and regulatory prospects for CYP-001 and CYP-004, the consistent safety profile may help inform future development decisions and potential applications of Cynata’s iPSC-derived MSC platform.

What This Means for Patients

The results are a setback for patients with acute graft‑versus‑host disease and knee osteoarthritis, both conditions that severely compromise quality of life and have limited treatment options. In aGvHD, steroid‑refractory patients remain at high risk of serious complications, while OA sufferers face persistent pain and progressive loss of mobility.

Although CYP‑001 and CYP‑004 did not outperform controls, both maintained favorable safety profiles with no new concerns. These findings underscore the difficulty of developing effective cell therapies for complex diseases, while offering insights that may guide future research and refinement of Cynata’s iPSC‑derived MSC platform.

Reference

Cynata’s Pivotal aGvHD and Osteoarthritis Trials Miss Primary Endpoints